Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Rao, J S ^a   Gujrati, M ^a   Chetty, C ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiogenesis; Glioma; Lipid raft; Migration; Soluble uPAR

Indexed keywords

GANGLIOSIDE GM1; UROKINASE RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL MEMBRANE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

EID: 84879908644     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.19     Document Type: Article

References (50)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286. (Pubitemid 46505878)
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410. (Pubitemid 37328844)
3. Lamalice L, Le BF, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007; 100: 782-794. (Pubitemid 46555683)
4. Ossowski L. Effect of antisense inhibition of Urokinase receptor on malignancy. Curr Top Microbiol Immunol 1996; 213: 101-112. (Pubitemid 26168567)
5. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928. (Pubitemid 28364031)
6. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008; 1785: 182-206.
7. Kiyan J, Smith G, Haller H, Dumler I. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts. Biochem J 2009; 423: 343-351.
8. Margheri F, Chilla A, Laurenzana A, Serratì S, Mazzanti B, Saccardi R et al. Endothelial progenitor cell-dependent angiogenesis requires localization of the fulllength form of uPAR in caveolae. Blood 2011; 118: 3743-3755.
9. Carlin SM, Resink TJ, Tamm M, Roth M. Urokinase signal transduction and its role in cell migration. FASEB J 2005; 19: 195-202. (Pubitemid 40189260)
10. Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM et al. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004; 94: 1562-1570. (Pubitemid 38856963)
11. Lu H, Mabilat C, Yeh P, Guitton JD, Li H, Pouchelet M et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996; 380: 21-24. (Pubitemid 26059972)
12. Fibbi G, Caldini R, Chevanne M, Pucci M, Schiavone N, Morbidelli L et al. Urokinasedependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest 1998; 78: 1109-1119. (Pubitemid 28440827)
13. Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M et al. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One 2010; 5: e12458.
14. Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R, Kramer MD. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer 1998; 77: 1638-1641. (Pubitemid 28230465)
15. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator- receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004; 24: 4147-4161. (Pubitemid 40468721)
16. Salajegheh M, Rudnicki A, Smith TW. Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol 2005; 13: 184-189. (Pubitemid 40726857)
17. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008; 13: 6752-6762.
18. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39. (Pubitemid 38018594)
19. Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007; 44: 65-102.
20. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121: 2307-2316. (Pubitemid 47585614)
21. Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK, Fassett D et al. Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther 2010; 9: 2605-2617.
22. Badiga AV, Chetty C, Kesanakurti D et al. MMP-2 siRNA inhibits radiationenhanced invasiveness in glioma cells. PLoS One 2011; 6: e20614.
23. Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 2011; 9: 377-389.
24. Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, Rao JS. Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res 2008; 68: 4736-4745.
25. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98: 3860-3863.
26. Liu D, Aguirre GJ, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1: 445-457. (Pubitemid 41039125)
27. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
28. Smith HW, Marra P, Marshall CJ. uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol 2008; 182: 777-790.
29. Kjoller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 2001; 152: 1145-1157. (Pubitemid 34280173)
30. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4: 67-79. (Pubitemid 36904162)
31. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 157-172.
32. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-342. (Pubitemid 46437793)
33. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843-1849. (Pubitemid 28217457)
34. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874. (Pubitemid 29252303)
35. Fernebro E, Madsen RR, Ferno M, Bru? nner N, Bendahl P, Christensen IJ et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37: 486-491. (Pubitemid 32232113)
36. Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011; 11: 448.
37. Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995; 129: 335-344.
38. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943. (Pubitemid 35477371)
39. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 686-692. (Pubitemid 34832148)
40. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 2003; 278: 46692-46698. (Pubitemid 37452247)
41. Piccolella M, Festuccia C, Millimaggi D, Locatelli A, Bologna M, Motta M et al. suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion. Int J Oncol 2008; 32: 185-191. (Pubitemid 351176077)
42. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277: 46932-46939. (Pubitemid 36159197)
43. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004; 117: 2909-2916. (Pubitemid 39117666)
44. Myohanen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G et al. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 1993; 41: 1291-1301. (Pubitemid 23239093)
45. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999; 144: 1285-1294. (Pubitemid 29157305)
46. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001; 12: 2975-2986. (Pubitemid 33062955)
47. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003; 9: 1565-1574. (Pubitemid 36758315)
48. Ma Z, Thomas KS, Webb DJ, Moravec R, Salicioni AM, Mars WM et al. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J Cell Biol 2002; 159: 1061-1070. (Pubitemid 36055760)
49. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol 2005; 7: 164-176. (Pubitemid 40590516)
50. Bagrodia S, Taylor SJ, Creasy CL, Chernoff J, Cerione RA. Identification of a mouse p21Cdc42/Rac activated kinase. J Biol Chem 1995; 270: 22731-22737.